FDA Mandates New Warning for GLP-1 Drugs, Including Ozempic, Regarding Rare Eye Condition
The Food and Drug Administration (FDA) has mandated that Ozempic and all other GLP-1 drugs sold in the United States must now include a warning about a rare eye condition known as nonarteritic anterior ischemic optic neuropathy (NAION). This condition, often described as a 'stroke in the eye,' results from a sudden reduction of blood flow to the optic nerve, leading to damage and potentially permanent vision loss, typically in one eye. The warning applies to a range of GLP-1 medications, including Ozempic, Wegovy, Mounjaro, and Zepbound. The FDA's review of 126 clinical trials, involving over 134,000 patients, found approximately 6.4 cases of NAION per 100,000 GLP-1 users annually, compared to about 3.8 cases among those on a placebo or other diabetes drugs. While the FDA has not definitively proven that these drugs cause NAION, and a mechanism for such a link has not been identified, the agency emphasizes the importance of patient awareness regarding symptoms like sudden vision loss, blurry spots, or tunn...